Vitamin C (ascorbic acid vs buffered vs liposomal) trials recruiting now

Who the trial lists, as registered

Lists people 18 and older. Conditions: Community-acquired Pneumonia, Influenza, COVID-19.

• Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
• symptoms or signs or both that are consistent with lower respiratory tract infection AND
• Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
• Up to 48 hours after ICU admission, receiving organ support with one or more of:

11 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Ceftriaxone; Moxifloxacin or Levofloxacin; Piperacillin-tazobactam; Ceftaroline; Amoxicillin-clavulanate; Standard course macrolide; Extended course macrolide; No systemic corticosteroid; Fixed-duration Hydrocortisone; Shock-dependent hydrocortisone; Fixed-duration higher dose Hydrocortisone; No antiviral agent for influenza; Five-days oseltamivir; Ten-days oseltamivir; No antiviral agent for COVID-19; Lopinavir / Ritonavir; Hydroxychloroquine; Hydroxychloroquine + lopinavir/ritonavir; Ivermectin; No immune modulation for COVID-19; Interferon beta-1a; Anakinra; Tocilizumab; Sarilumab; Local standard venous thromboprophylaxis; Therapeutic dose anticoagulation; Conventional low dose thromboprophylaxis; Intermediate dose thromboprophylaxis; Continuation of therapeutic dose anticoagulation; No immunoglobulin; Convalescent plasma; Delayed administration of convalescent plasma; No vitamin C; Vitamin C; No antiplatelet; Aspirin; P2Y12 inhibitor; No simvastatin; Simvastatin; Eritoran; Apremilast; Clinician-preferred mechanical ventilation strategy; Protocolised mechanical ventilation strategy; No renin-angiotensin system inhibitor; Angiotensin converting enzyme inhibitor; Angiotensin Receptor Blockers; ARB + DMX-200; No cysteamine; Cysteamine; Fixed-duration dexamethasone; Baloxavir Marboxil; Five-days oseltamivir + baloxavir marboxil; Ten-days oseltamivir + baloxavir marboxil; No endothelial modulator; Imatinib; No Immune Modulator for Influenza; Tocilizumab; Baricitinib; No antiviral agent for COVID-19; Nirmatrelvir/ritonavir; Remdesivir; Nirmatrelvir/ritonavir + remdesivir

Registered summary

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Where, as registered

11 US sites in 11 states; also United Kingdom (153), Australia (59), Canada (40), France (24), Netherlands (19), Germany (17), New Zealand (11), Japan (10), Spain (10), Italy (8), Ireland (5), Pakistan (5), India (4), Nepal (4), Belgium (3), Croatia (3), Israel (3), Portugal (3), Serbia (3), Czechia (2), Finland (2), Hungary (2), Slovenia (2), Colombia (1), Estonia (1), Romania (1), Saudi Arabia (1), Switzerland (1).

Who the trial lists, as registered

Lists people 18 and older. Conditions: Clonal Cytopenia of Undetermined Significance; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Lymphoma; Chronic Myelomonocytic Leukemia.

• Age >= 18 years
• Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that occurred after having a response to the last therapy that lasted > 6 months; refractory is no response or relapse within 6 months; previous biopsies < 6…
• NOTE: Arms A/B - relapsed or refractory DLBCL within 24 months from the end of anthracycline-based therapy; no prior salvage therapy; patients can have received radiation therapy as part of initial treatment but not specifically for relapse
• NOTE: Arm C patients include relapsed or refractory lymphoma patients of any type for which the recommended treatment includes one of the platinum-based regimens; of note, relapsed or refractory double-hit high grade lymphoma patients and…

73 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Ascorbic Acid; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Gemcitabine Hydrochloride; Ifosfamide; Laboratory Biomarker Analysis; Oxaliplatin; Placebo Administration; Questionnaire Administration; Rituximab; Decitabine; Biospecimen Collection; Core Biopsy; Bone Marrow Aspiration; Bone Marrow Biopsy; Echocardiography; Positron Emission Tomography; Magnetic Resonance Imaging; Central Venous Cannula Insertion; Portacath Placement; Computed Tomography; Decitabine and Cedazuridine

Registered summary

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The full summary is on the listing.

Where, as registered

4 US sites in 2 states.

Who the trial lists, as registered

Lists people 18 and older. Conditions: Metastatic Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8.

• Histologically or cytologically confirmed microsatellite stable (MSS) metastatic colorectal adenocarcinoma with any KRAS mutation (as determined by a Clinical Laboratory Improvement Act \[CLIA\]-certified lab), including metastases to…
• Disease progression, intolerance or contraindication to a fluoropyrimidine, oxaliplatin, irinotecan
• ≥ 18 years of age
• Performance status Eastern Cooperative Oncology Group (ECOG) 0-1

16 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Balstilimab; Biospecimen Collection; Botensilimab; Computed Tomography; Dietary Intervention; Magnetic Resonance Imaging; Vitamin C

Registered summary

This phase Ib trial tests the safety, side effects, and effectiveness of botensilimab, and balstilimab in combination with a fasting mimicking diet and high dose vitamin C in treating patients with KRAS-mutant metastatic colorectal cancer. Botensilimab and balstilimab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. KRAS is protein found on some tumor cells that is involved in the growth of tumor cells. KRAS mutant cells have been found to be more sensitive to vitamin C induced growth suppression in the presence of low-sugar (glucose). The full summary is on the listing.

Where, as registered

3 US sites in 1 state.

Who the trial lists, as registered

Lists people 6 to 16. Conditions: Asthma; Pulmonary Function; Wheezing; In Utero Nicotine.

• Women and their offspring randomized to vitamin C versus placebo during pregnancy as well as pregnant nonsmokers and their offspring enrolled as the reference group in the original VCSIP study

The exclusion criteria are on the listing.

What it tests, as registered

No active intervention in this protocol (previously randomized to Vitamin C); No active intervention in this protocol (previously randomized to Placebo)

Registered summary

The overall aims of this protocol are to determine whether prenatal supplementation with vitamin C to pregnant smokers can improve pulmonary function at 10 years of age in their offspring. This is an additional continuation of the Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) trial, to follow the offspring through 10 years of age. The hypothesis for this protocol is an extension of the VCSIP trial that supplemental vitamin C in pregnant smokers can significantly improve their children's airway function tests. The full summary is on the listing.

Where, as registered

2 US sites in 2 states.

Who the trial lists, as registered

Lists people 18 to 80; healthy volunteers accepted. Conditions: Kidney Stones; Kidney Calculi; Urolithiasis; Urolithiasis, Calcium Oxalate; Nephrolithiasis; Nephrolithiasis, Calcium Oxalate; Oxalate Urolithiasis; Healthy; Healthy Volunteer.

• age 18-80 yrs
• Body Mass Index > 18.5 kg/m2
• Normal fasting serum electrolytes on comprehensive metabolic profile
• Willing to ingest fixed diets

2 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Low-oxalate diet and glycolate dosing; Oral glycolate dosing; Oral 13C- ascorbic acid dosing

Registered summary

The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate. The study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones. The full summary is on the listing.

Where, as registered

2 US sites in 2 states.

Who the trial lists, as registered

Lists people 18 and older. Conditions: Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Breast Cancer Metastatic; Breast Cancer Stage IV; Pancreatic Cancer Stage IV; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Adenocarcinoma of the Breast; PALB2 Gene Mutation; Pancreas Cancer, Metastatic; Pancreas Cancer, Recurrent; Pancreas Cancer; Stage IV Pancreatic Cancer; Stage 4 Pancreatic Cancer.

• Age ≥ 18 years.
• Pancreatic or breast cancer, as described below.
• Stage IV (based on AJCC staging guidelines) at the time of enrollment. a. Note that potential subjects with stage IV cancer that have had a complete response from prior chemotherapy are still potentially eligible.
• Expected survival time ≥ 6 months, as determined by the investigator.

31 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Melphalan; BCNU; Vitamin B12B; Vitamin C; Autologous Hematopoietic Stem Cells

Registered summary

The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitamin C with autologous hematopoietic stem cell infusion. A dose-escalation schedule is being employed for the vitamin C.

Where, as registered

2 US sites in 2 states.

Who the trial lists, as registered

Lists people 18 and older. Conditions: Open Posterior Thoracolumbar Spinal Fusion Procedure.

• Any patient older than 18 years old
• Scheduled for an open posterior thoracolumbar spinal fusion procedure

The exclusion criteria are on the listing.

What it tests, as registered

Tranexamic Acid Injectable Product (1000 mg intravenous bolus); Vitamin C 250 MG Oral Tablet; Tranexamic Acid 650Mg Tablet

Registered summary

As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or different method of delivery like intravenous (IV) TXA reduces the postoperative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 25 to 75; healthy volunteers accepted. Conditions: Healthy; Suboptimal Vitamin C Levels; Adequate Vitamin C Levels.

• Provide voluntary, written, informed consent to participate in the study.
• Agree to provide a valid cell phone number and are willing to receive communications through text.
• Can read and write English.
• Willing to complete questionnaires, records, and diaries associated with the study.

4 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Qualia Vitamin C+; Placebo

Registered summary

This is a double-blind, placebo-controlled, parallel-group, study evaluating the effect of a Qualia Vitamin C+ formulation on Whole Blood Vitamin C levels in the blood of healthy adults aged 25 years or older that have suboptimal vitamin C blood levels (i.e., 0.4 - 0.9 mg/dL) and those with adequate vitamin C blood levels (≥0.9 mg/dL). Approximately 152 (76 in the suboptimal stratum and 76 in the adequate stratum) participants will be assigned to one of two study arms: Qualia Vitamin C+ or placebo. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 40 to 85. Conditions: Longevity; GLP-1; Geroscience; Aging.

• Existing AgelessRx patient
• Adults (40 - 85 years of age)
• Any sex
• Any ethnicity

3 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Metformin; Rapamycin; Naltrexone; Vitamin C

Registered summary

The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications. The main questions it aims to answer are: * Whether the combination of metformin, with or without rapamycin or low-dose naltrexone, will be adequate to maintain the relative weight of individuals gradually discontinuing GLP-1 receptor agonist use. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 18 and older. Conditions: Iron Deficiency Anemia.

• Aged ≥ 18 years
• Patients who have undergone a Roux-en Y Gastric Bypass or Vertical Sleeve Gastrectomy and are at least 3 months or more out from surgery.
• Iron deficiency anemia defined as iron deficient with either ferritin<30 mcg/l, TSAT<20%, or anemia with Hgb<13 g/dL for both males and females.
• Willingness to participate and signing the informed consent form.

The exclusion criteria are on the listing.

What it tests, as registered

Ferumoxytol; Saline; Ferrous sulfate tablets; Vitamin C

Registered summary

Given the limited long-term effectiveness of traditional weight loss methods, bariatric surgery is increasingly becoming the preferred option for sustained weight loss. With the ascendancy of the laparoscopic approach, the two most common procedures are the Roux-en-Y gastric bypass (RYGB) and the vertical sleeve gastrectomy (VSG). The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 18 to 89; healthy volunteers accepted. Conditions: Spinal Cord Injuries; Cardiovascular Diseases; Endothelial Dysfunction.

• Men and women of all races, ethnic backgrounds>18 years of age
• Traumatic spinal cord injury (Sports, Assault, Transport, Fall, Other Traumatic Causes)
• Time since injury (> 12 months)
• Paraplegia Motor Complete Injury (neurological level of injury at T2 or below, ASIA Impairment Scale A or B

The exclusion criteria are on the listing.

What it tests, as registered

Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid); venous occlusion plethysmography; Acetylcholine; Sodium Nitroprusside; Ascorbic acid; venous phlebotomy

Registered summary

Individuals with spinal cord injury have heart attacks and strokes more frequently, and much earlier in life. People with spinal cord injuries develop plaque in vessels much faster, and the reasons why are unclear. Doctors generally attributed the increased risk with weight gain and developing diabetes, but many studies have shown that even without these common factors, plaque in vessels is developing more often and faster. Endothelial cells are a single layer of cells that line all vessels in the body and plays an important role in vessel health. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 18 to 79. Conditions: Obesity.

• Obese: BMI >25 m/kg2
• Elevated insulin resistance: HOMA-IR > 2.5 (calculation based on fasting glucose and insulin concentrations in blood)
• Middle-aged: 35-65 years
• Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.

1 more inclusion criterion and the exclusion criteria are on the listing.

What it tests, as registered

ascorbic acid

Registered summary

In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an innovative, moment-to-moment assessment of the blood pressure response following individual bursts of muscle sympathetic nerve activity (MSNA), (10, 11, 34, 37). The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 18 to 79; healthy volunteers accepted. Conditions: Blood Pressure; Hypertension.

• Lean: BMI < 25 kg/m
• Normal insulin sensitivity: (calculation based on fasting glucose and insulin concentrations in blood)
• Middle-aged: 18-79 years
• Blood pressure: < 140 (systolic) and < 90 mmHg (diastolic

3 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Dextrose 20 % in 500 ML Injection; Intralipid; Saline; Ascorbic acid

Registered summary

The purpose of our study is to understand the extent to which the blood vessels are affected by glucose and fat (lipids) in lean healthy adults and if these changes in the blood vessels contribute to the development of high blood pressure.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists female participants 18 to 45; healthy volunteers accepted. Conditions: Preeclampsia; Endothelial Function.

• 18-24 years old,
• 12 weeks - 5 years post pregnancy
• one of the following:
• history of a normal pregnancy with a current diagnosis of depression,

3 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Paroxetine Hydrochloride; Ascorbic acid (Vitamin C)

Registered summary

Preeclampsia is a condition in pregnancy where a woman develops high blood pressure and other complications. Women who develop preeclampsia are 4 times more likely to have heart disease later in life. They are also more likely to have depression after pregnancy. Why they are more likely to develop these conditions is not known. It may be because their blood vessels were damaged during pregnancy. Changes in blood vessel health can predict heart disease. These changes have been recorded after pregnancy in women who had preeclampsia. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 18 to 50. Conditions: Adequate Vitamin C Status; Inadequate Vitamin C Status.

• English speaking
• Men and women between 18-50 years of age
• BMI 30-40 kg/m²
• Resting blood pressure <140/90 mm Hg

3 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Vitamin C Supplement + Low Vitamin C Diet; Placebo + Low Vitamin C Diet

Registered summary

This study is testing whether taking vitamin C every day can help improve gut health and reduce inflammation in adults with obesity. Poor gut health-sometimes called "leaky gut"-can allow harmful substances from bacteria to enter the bloodstream, which may lead to inflammation and increase the risk of heart disease and liver problems. Participants will complete two study periods, each lasting two weeks, with a two-week break in between. In one period, they will take vitamin C; in the other, a placebo. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 35 to 65. Conditions: Hypertension; Cardiovascular Diseases.

• Obese: BMI >30 m/kg2
• Middle-aged: 35-65 years
• Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
• Able and willing to provide written informed consent

The exclusion criteria are on the listing.

What it tests, as registered

Ascorbic acid solution (American Regent Laboratories Inc.); Saline

Registered summary

The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD). This study is testing the health of the blood vessels and the activity of the nerves that control the blood vessels in adults with insulin resistance. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists female participants 20 to 45. Conditions: Diminished Ovarian Reserve; IVF Outcomes.

• Infertile women undergoing their 1st or 2nd IVF treatment
• Diagnosed with DOR: POSEIDON criteria (AMH <1.2 ng/mL or bilateral AFC <5) BMI between 18.5-28.0 kg/m²
• Signed informed consent

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin C; Placebo

Registered summary

In the context of the accelerating aging population and the continuous decline in birth rates nationwide, delaying reproductive aging in women and protecting the fertility of women of childbearing age have become urgent issues and key demands that need to be addressed in the field of maternal and child health in China. The ovaries have reproductive and hormone secretion functions and are crucial throughout the female reproductive lifecycle. The full summary is on the listing.

Where, as registered

No US site; China (6).

Who the trial lists, as registered

Lists people 18 and older. Conditions: Pain, Acute.

• Aged 18 and over;
• Treated in ED for acute musculoskeletal pain present for less than 2 weeks;
• Discharged with an opioid prescription;
• Speaks French or English.

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin C; Placebo

Registered summary

Recent evidence has shown that vitamin C has some analgesic properties and can therefore reduce opioids used during healing. Vitamin C analgesic effect has been explored mostly during the short-term postoperative context or in disease specific chronic pain prevention but not after acute musculoskeletal injuries, which are often seen in the emergency department (ED). The study's primary aim is to compare the total morphine 5 mg equivalent pills consumed during a two-week follow-up between patients receiving vitamin C or a placebo after ED discharge for an acute musculoskeletal pain complaint. The full summary is on the listing.

Where, as registered

No US site; Canada (1).

Who the trial lists, as registered

Lists people 18 to 75. Conditions: Colorectal Cancer; Vitamin C; GLUT3.

• Age≥18 years, ≤75 years; Histologically proven peritoneal metastatic adenocarcinoma of colorectal cancer, unresectable metastatic disease; IHC confirmed strong positive GLUT3; measurable disease; Eastern Cooperative Oncology Group (ECOG)…

The exclusion criteria are on the listing.

What it tests, as registered

Ascorbic acid; FOLFOX Protocol; Adebrelimab

Registered summary

Previous preclinical study has shown that high levels of ascorbic acid (AA) possesses the ability to kill human colorectal cancer cells and high expression of GLUT3 will augment the efficacy of AA. To date, no previous studies have investigated the combination of therapeutic role of AA and PD-L1 antibody in metastatic colorectal cancer with high expression of GLUT3. The full summary is on the listing.

Where, as registered

No US site; China (1).

Who the trial lists, as registered

Lists people 18 and older. Conditions: Chronic Pain; Knee Pain Chronic; Post Operative Pain.

• Patients >18 years old
• Undergoing a unilateral or bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin C; Placebo

Registered summary

Phase II Multicentre, pilot, parallel-group, blinded, 1:1 randomized controlled trial to determine the feasibility of conducting a larger definitive trail of using vitamin C to reduce persistent pain in patients undergoing total knee arthroplasty surgery.

Where, as registered

No US site; Canada (3).

Who the trial lists, as registered

Lists people 18 to 70; healthy volunteers accepted. Conditions: Ageing.

• Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes).
• Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
• Weight: BMI within the range of 18.5-28 kg/m².
• Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol.

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin C; Placebo

Registered summary

The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The full summary is on the listing.

Where, as registered

No US site; China (3).

Who the trial lists, as registered

Lists people 18 to 85. Conditions: Septic Shock.

• Age ≥18 and < 85 years old
• Admitted to ICU
• Diagnosis of patients with SEPSIS 3.0 (diagnostic criteria) 4, SOFA score is 2-13 points

The exclusion criteria are on the listing.

What it tests, as registered

vitamin B6+ Vitamin B12 +vitamin C; vitamin B6+ Vitamin B12; vitamin C; 0.9%Nacl

Registered summary

Sepsis is a kind of disease with high morbidity and mortality in ICU. At present, there is no specific treatment, and its pathogenesis is mainly excessive oxidative stress. Anti-inflammatory, antioxidant and immune-regulating drugs may produce better therapeutic effects, while vitamin B6, vitamin B12 and vitamin C have anti-inflammatory, antioxidant and immune-regulating effects. The full summary is on the listing.

Where, as registered

No US site; China (1).

Who the trial lists, as registered

Lists people 18 and older. Conditions: Cardiac Arrest.

• patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min;
• and treated with a norepinephrin or an epinephrin continuous infusion during at least 30 min before randomization to maintain mean arterial pressure (MAP) ≥ 65 mmHg.

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine); standard treatment

Registered summary

Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. The full summary is on the listing.

Where, as registered

No US site; France (14).

Who the trial lists, as registered

Lists people 18 and older. Conditions: Pain, Acute.

• Age ≥ 18 years old
• Presenting to the ED with acute MSK pain of ≤ 48 hours duration at triage
• Verbal numerical rating scale pain intensity at triage of ≥ 4 on a 0-10 scale
• Triaged to the ambulatory section of the ED

1 more inclusion criterion and the exclusion criteria are on the listing.

What it tests, as registered

Vitamin C; Placebo

Registered summary

Musculoskeletal (MSK) injuries such as sprains, strains, bruises, and fractures are among the most common reasons people visit the emergency department. These injuries often cause significant pain in the first few days, making it difficult to move, work, or sleep. Usual pain medications like ibuprofen or acetaminophen can help, but they are not safe or effective for everyone. Some people cannot take them because of heart, kidney, stomach, or liver problems. Others still experience strong pain despite treatment. The full summary is on the listing.

Where, as registered

No US site; Canada (4).

Who the trial lists, as registered

Lists people 18 to 85. Conditions: Corneal Endothelial Cell Loss; Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery.

• The subject must voluntarily sign and date a Human Research Ethics Committee (HREC) approved informed consent form (ICF) prior to the initiation of any screening or study-specific procedures.
• In the Investigator's opinion, the subject is willing and able to comply with study instructions and complete all scheduled study visits.
• Male or female aged ≥18 and ≤85 years.
• Scheduled to undergo cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens.

7 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Ophthalmic solution (matching formulation without ascorbic acid); Ascorbic acid ophthalmic solution 5%

Registered summary

This study is designed to assess whether an investigational eye drop called CA201A can help protect the cornea (the outer covering of the eye) and reduce damage to corneal endothelial cells following cataract surgery, without causing significant side effects. Cataract surgery is one of the common surgical procedures, however, it can sometimes lead to a loss of corneal endothelial cells, which are essential for maintaining the corneal clarity and long-term eye health. The full summary is on the listing.

Where, as registered

No US site; Australia (8).

Who the trial lists, as registered

Lists people 18 and older. Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia.

• Patients eligible for treatment with azacitidine with one of the following diagnoses according to World Health Organization 2016:
• MDS Higher-risk MDS according to the IPSS-R, i.e., intermediate- to very high-risk (IPSS-R score > 3)
• CMML CMML with 10-29 percent marrow blasts without myeloproliferative disorder
• AML AML with 20-30 percent blasts (low-blast count AML)

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin C; Placebo

Registered summary

This is a multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in patients with higher-risk MDS, CMML-2 or low-blast count AML. The primary purpose is to investigate if oral vitamin C supplementation to azacitidine, compared with azacitidine + placebo, can increase the effectiveness of epigenetic therapy in patients with higher-risk myeloid malignancies, who are not candidates for allogeneic hematopoietic stem cell transplantation.

Where, as registered

No US site; Denmark (6), Sweden (4).

Who the trial lists, as registered

Lists female participants 18 to 80. Conditions: Catheter-Associated Urinary Tract Infection.

• Nonpregnant women
• 18 years of age or older
• Undergoing elective GYN surgery

The exclusion criteria are on the listing.

What it tests, as registered

Ascorbic Acid 1000 MG; Placebo

Registered summary

Double-blind placebo-controlled randomized trial aiming to assess the role of Vitamin C supplementation in the prevention of catheter-associated urinary tract infections in women undergoing elective gynecological surgeries.

Where, as registered

No US site; Russia (1).

Who the trial lists, as registered

Lists people 18 and older; healthy volunteers accepted. Conditions: Healthy Volunteers; Dietary Supplementation; Skin Health; Health Status; Antioxidants.

• Chinese adults of Asian descent aged 18 and above;
• Daily fruit and vegetable intake < 240g (calculated based on the fruit and vegetable section of the food frequency questionnaire);
• S3 measurement index < 30000;
• Participants must possess basic Chinese reading comprehension and expression skills, and be able to independently complete questionnaire surveys;

2 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Vitamin C & Green Tea Capsules + Multivitamin & Mineral Capsules Combination; Placebo Combination (Matching)

Registered summary

This is a randomized, double-blind, placebo-controlled clinical trial exploring the effects of a 12-week dietary supplement regimen on skin condition and perceived overall health status. The study will involve 120 healthy Chinese adults aged 18 and above with low daily fruit and vegetable intake. Participants will be randomly assigned to one of two groups: one group will take a combination of Nu Skin's Vitamin C \& Green Tea Capsules and Multivitamin \& Mineral Capsules, while the other group will take a matching placebo. The full summary is on the listing.

Where, as registered

No US site; China (1).

Who the trial lists, as registered

Lists people 2 months to 59 months. Conditions: Pneumonia Childhood; Vitamin C; Hospital Stay Time.

• presenting with severe pneumonia
• ≤ 48-hours duration

The exclusion criteria are on the listing.

What it tests, as registered

Antibiotics administration; Vitamin C

Registered summary

Severe pneumonia is a common and serious illness in young children and often requires hospital admission. This clinical trial aims to find out whether adding vitamin C to standard treatment can reduce the length of hospital stay in children under five years of age admitted with severe pneumonia. The full summary is on the listing.

Where, as registered

No US site; Pakistan (1).

Who the trial lists, as registered

Lists people 18 to 65; healthy volunteers accepted. Conditions: Skin Condition; Anti-Oxidative Stress.

• Healthy male or female adults, aged 18-65 years old;
• Commitment not to use products having activity comparable with that of the product to be tested during the study period;
• Free of any dermatological or systemic disorder that would interfere with results.

The exclusion criteria are on the listing.

What it tests, as registered

Placebo sachet; Vitamin C and Glutathione Liquid Sachet

Registered summary

The objective of this study is to evaluate the effect of liquid vitamin C and glutathione supplements on human skin condition improvement and anti-oxidation.

Where, as registered

No US site; Taiwan (1).

Who the trial lists, as registered

Lists people 18 and older; healthy volunteers accepted. Conditions: Gingival Pigmentation; Depigmentation; Vitamin C; Glutathione.

• Score0:absence of pigmentation
• Score1:spotsofbrowntoblackcolororpigments
• Score2:browntoblackpatchesbutnotdiffusepigmentation
• Score3:diffuse brown to black pigmentation,marginal,and attached.

4 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Vitamin c and glutathione; Surgical depigmentation

Registered summary

It is a clinical study conducted to evaluate the effect of vitamin C and Glucathonine injection of pigmented gingival tissue versus surgical removal by scalpel

Where, as registered

No US site; Egypt (1).

Who the trial lists, as registered

Lists people 18 to 65; healthy volunteers accepted. Conditions: Short Chain Fatty Acids Concentration in Stools; Gut Microbiota Diversity and Composition.

• Healthy individuals aged 18-65 years with a BMI between 18.5-35 Kg/m2
• Self-reported good health with no chronic conditions requiring regular medical care
• Willing to provide blood, urine, and stool samples at multiple time points

The exclusion criteria are on the listing.

What it tests, as registered

Moderate Vitamin C dose (200 mg); High-dose vitamin C supplementation (1000 mg); Habitual diet (run in period)

Registered summary

The aim of this dietary intervention study is to explore how vitamin C affects the bacteria that live in our gut. Vitamins are essential nutrients found in fruits and vegetables. Our bodies cannot make them on their own, but we need them to function correctly. Vitamins play various roles, including supporting the immune system and assisting with energy production. Some vitamins in our diet can reach the large intestine, where they may be used by gut bacteria to promote their growth. The full summary is on the listing.

Where, as registered

No US site; United Kingdom (1).

Who the trial lists, as registered

Lists people 18 to 45; healthy volunteers accepted. Conditions: Depigmentation Treatment; Depigmentation.

• Systemically healthy patient of both genders aged from 18-45 years.
• Presence of bilateral physiologic gingival pigmentation in the anterior maxillary or mandibular region DOPI grades III-IV only.
• Good oral hygiene.
• Thick gingival phenotype.

The exclusion criteria are on the listing.

What it tests, as registered

surgical depigmentation; Coenzyme Q10; Vitamin C; Surgical Gingival Depigmentation Coenzyme Q10 Vitamin C

Registered summary

This study aims to assess the clinical effectiveness of Co-enzyme Q10 and Vitamin C, applied individually or in combination after surgical gingival depigmentation.

Where, as registered

No US site; Egypt (1).

Who the trial lists, as registered

Lists people 6 to 21; healthy volunteers accepted. Conditions: Hypovitaminosis D.

• 1\. 6 to 21 years old (inclusive) 2. Patients 63.5 kg (140 lbs) and up 3. Patients not currently taking vitamin D supplements

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin D3, Calcium, and Vitamin C

Registered summary

Vitamin D is essential for calcium absorption and bone growth, brain development, and immune system function. Vitamin D is produced by the body in response to natural sunlight. In New Jersey, which is not near the equator and where children are indoors for large parts of the year or use of sun block, it is possible that otherwise healthy children may suffer from vitamin D deficiency, placing them at risk for weak bones, fractures and poor bone growth. Larger children are at a higher risk of deficiency. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 16 and older. Conditions: Vaccine Adverse Reaction; Post Acute Covid-19 Vaccination Syndrome.

• Persistent fatigue lasting more than 6 months
• Received at least one dose of a Covid-19 vaccine, after which they experienced fatigue symptoms (symptom onset within two weeks of vaccination)
• Laboratory result showing persistent spike protein in blood OR presence of spike protein antibodies with SARS-CoV-2 nucleocapsid antibodies negative.

The exclusion criteria are on the listing.

What it tests, as registered

Combined metabolic modulator; Rice Protein Powder with Vitamin C

Registered summary

The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults diagnosed with post-acute Covid-19 vaccination syndrome (PACVS), a condition characterized by persistent fatigue and exercise intolerance attributed to Covid-19 vaccination and confirmed by laboratory testing. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 18 and older. Conditions: Pyruvate Kinase Deficiency; Glucose 6 Phosphate Dehydrogenase Deficiency.

• Confirmed diagnosis of Pyruvate Kinase Deficiency (PKD) or Class A glucose-6-phosphate dehydrogenase (G6PD A) as verified by genetic mutation documentation or enzymatic testing
• 18 years of age or older
• Able to take oral medications either by mouth or via gastrostomy tube
• Willing and able to provide written informed consent prior to any study procedures

1 more inclusion criterion and the exclusion criteria are on the listing.

What it tests, as registered

Vitamin C

Registered summary

This study is testing whether high-dose Vitamin C is safe and well-tolerated in patients with two inherited red blood cell disorders - Pyruvate Kinase Deficiency (PKD) and Class A Glucose-6-Phosphate Dehydrogenase Deficiency (G6PDA). Both conditions cause red blood cells to break down too quickly, leading to anemia and related complications. Our earlier research showed that a single oral dose of Vitamin C (250 mg, 500 mg, or 750 mg) reduced red blood cell breakdown by approximately 50% within one hour. The full summary is on the listing.

Where, as registered

1 US site in 1 state.

Who the trial lists, as registered

Lists people 40 to 80. Conditions: COPD (Chronic Obstructive Pulmonary Disease).

• Age 40-80 years (including 40 and 80).
• Patients with COPD classified as GOLD stages 2-4:
• No respiratory infection or acute exacerbation of COPD within 4 weeks prior to enrollment. Acute exacerbation is defined as an acute worsening of respiratory symptoms requiring additional treatment.
• The patient voluntarily consents to participate in the study, is capable of verbal or written communication, and can understand and sign the informed consent form.

The exclusion criteria are on the listing.

What it tests, as registered

Vitamin C (Ascorbic Acid); Placebo

Registered summary

This multicenter, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy of Vitamin C supplementation in improving the prognosis of patients with Chronic Obstructive Pulmonary Disease (COPD) through its antioxidant effects. The primary objectives of the study are to determine: 1. Whether Vitamin C reduces the frequency of acute COPD exacerbations. 2. Whether Vitamin C improves pulmonary function and health-related quality of life in patients with COPD. The full summary is on the listing.

Where, as registered

No sites listed yet.

Who the trial lists, as registered

Lists people 18 to 75. Conditions: Post-acute Sequelae of SARS-COV-2 Infection.

• 1\. Age ≥18 years;
• 2\. Post-infection with SARS-CoV-2 for more than 3 months and meets the World Health Organization (WHO) definition of Long COVID;
• 3\. Symptom criteria: Meet the inclusion and exclusion criteria for each symptom cluster;
• 4\. Fertile female subjects are not breastfeeding or pregnant at the time of enrollment (negative urine pregnancy test);

16 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Prednisone; Budesonide/Formoterol; Vitamin C combined with Coenzyme Q10 oral treatment; Montelukast tablets oral treatment

Registered summary

This study is a prospective, randomized controlled, basket trial. Patients diagnosed with Post-Acute Sequelae of SARS-CoV-2 Infection who meet the inclusion and exclusion criteria are recruited and divided into three symptom clusters: Inflammatory Cardiac involvement symptoms cluster, cough symptoms cluster and fatigue symptoms cluster. Each symptom cluster is randomly divided into an experimental group and a control group, Patients who do not accept treatment can be included in the observational cohort. The full summary is on the listing.

Where, as registered

No US site; China (1).

Who the trial lists, as registered

Lists people 20 to 85. Conditions: Stroke; Bruises; Skin Lesions.

• Ischemic stroke patients.
• Aged 20 to 85 years.

The exclusion criteria are on the listing.

What it tests, as registered

Ascorbic acid (Vitamin C); Normal Saline (Placebo)

Registered summary

Background Over the past few decades, significant advances have been made in the diagnosis and treatment of strokes. Most studies focus on functional recovery in stroke patients. In addition to motor function, there are many symptoms may affect function and quality of life in stroke patients. Bruises are caused by damage to the skin that causes blood to drain out of the capillaries and accumulate in the connective tissue of the skin or subcutaneous tissue. The full summary is on the listing.

Where, as registered

No sites listed yet.

Who the trial lists, as registered

Lists female participants of any age. Conditions: Premature Ovarian Insufficiency; Ovarian Reserve Function.

• Regularity of menstruation changed for less than one year.
• 10U/L≤ FSH<25 U/L in two tests more than 4weeks aprt.
• AMH < 1.1 ng/mL.
• Bilateral ovarian AFC <7.

1 more inclusion criterion and the exclusion criteria are on the listing.

What it tests, as registered

Vitamin C (Ascorbic Acid); Vitamin C (Ascorbic Acid); Placebo

Registered summary

The goal of this clinical trial is to learn if Vitamin C works to improve ovarian reserve in women with ovarian aging. It will also learn about the safety of Vitamin C. The main questions it aims to answer are: * Does Vitamin C supplementation improve the ovarian reserve prediction score? * What medical problems do participants have when taking Vitamin C supplementation? Researchers will compare Vitamin C to a placebo (a look-alike substance that contains no drug) to see if drug Vitamin C works to improve ovarian reserve in women with ovarian aging. The full summary is on the listing.

Where, as registered

No sites listed yet.